Objectives:
Primary endpoints:
To achieve low levels of Polymerase Chain Reaction (PCR) ratios of B-cell antigen receptor
(Bcr-Abl)/Bcr (molecular CR) in a significant proportion of patients after 12 months of
higher doses (800 mg daily) of Gleevec therapy To increase the proportion of patients
achieving a complete cytogenetic response in patients with Ph-positive chronic phase CML
using initial higher dose Gleevec therapy.
Secondary endpoints:
To evaluate the durations of PCR negativity, cytogenetic response, hematologic control, and
survival.
To analyze differences in response rates and in prognosis within different risk groups and
patient characteristics